[Development of Ethylcellulose/Eudragit matrix for controlled and continuous release of insulin].
OBJECTIVE
Diabetes Type I is a chronic disease requiring insulin repeated injections by parenteral during a lifetime. This method of administration as well as traumatic can be a problem for adherence of patients to treatment. In order to overcome these difficulties, we considered the development of therapeutic transdermal drug delivery (TTDD) of insulin.


METHODS
As active ingredient we used anhydrous human insulin Actarapid HM from Novo Nordisk laboratory, the excipients are ethyl cellulose, Eudragit RS 100 and butylphtalate. We developed two matrix Ethylcellulose/Eudragit in reports 1 and 2, in which are incorporated different proportions of insulin.


RESULTS
The study of the release of insulin in phosphate buffer at pH 7.4, showed a continuous release profiles strongly depending on Ethylcellulose/Eudragit report and the initial charge of insulin.


CONCLUSIONS
This study shows that the matrix Ethylcellulose/Eudragit lends itself to the development of a controlled release of insulin. This allows us to continue this work by combining this matrix with other elements for achieving an insulin TTDD.
Mbaye
Gora
G
Laboratoire de Biophysique et de Physique Pharmaceutique, Faculté de Médecine de Pharmacie et d’Odontologie de Dakar, Université Cheikh Anta Diop de Dakar. mbaygo@yahoo.fr
Ndiaye
Augustin
A
Diouf
Louis Augustin Diaga
LA
Diallo
Abdoulaye Séga
AS
Diedhiou
Adama
A
Sene
Mbaye
M
Mbodj
Mamadou
M
Thioune
Oumar
O
Dieye
Amadou Moctar
AM
Diop
Ibrahima
I
Cisse
Aynina
A
Diarra
Mounibé
M
D002482:Cellulose / Q000031:analogs & derivatives; D016503:Drug Delivery Systems; D007328:Insulin / Q000008:administration & dosage*; D011109:Polymethacrylic Acids
D007328:Insulin; D011109:Polymethacrylic Acids; C038300:methylmethacrylate-methacrylic acid copolymer; C013517:ethyl cellulose; D002482:Cellulose